PremiumThe FlyRallybio discontinues RLYB212 program Rallybio’s Promising Developments and Financial Stability Justify Buy Rating Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating PremiumThe FlyRallybio announces initiation of dosing in RLYB212 Phase 2 trial Rallybio price target lowered to $7 from $8 at JMP Securities Rallybio to begin RLYB116 confirmatory clinical PK/PD study in Q2 PremiumThe FlyRallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved Rallybio participates in a conference call with JPMorgan Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee 
